Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Oct 9;2015(10):CD010790.
doi: 10.1002/14651858.CD010790.pub2.

Laser therapy for retinopathy in sickle cell disease

Kay Thi Myint  1 , Soumendra Sahoo, Aung Win Thein, Soe Moe, Han Ni
Affiliations
Meta-Analysis

Laser therapy for retinopathy in sickle cell disease

Kay Thi Myint et al. Cochrane Database Syst Rev. .

Update in

  • Laser therapy for retinopathy in sickle cell disease.
    Myint KT, Sahoo S, Thein AW, Moe S, Ni H. Myint KT, et al. Cochrane Database Syst Rev. 2022 Dec 12;12(12):CD010790. doi: 10.1002/14651858.CD010790.pub3. Cochrane Database Syst Rev. 2022. PMID: 36508693 Free PMC article.

Abstract

Background: Sickle cell disease includes a group of inherited haemoglobinopathies affecting multiple organs including the eyes. Some people with the disease develop ocular manifestations due to vaso-occlusion. Vision-threatening complications of sickle cell disease are mainly due to proliferative sickle retinopathy which is characterized by proliferation of new blood vessels. Laser photocoagulation is widely applicable in proliferative retinopathies such as proliferative sickle retinopathy and proliferative diabetic retinopathy. It is important to evaluate the efficacy and safety of laser photocoagulation in the treatment of proliferative sickle retinopathy to prevent sight-threatening complications.

Objectives: To evaluate the effectiveness of various techniques of laser photocoagulation therapy in sickle cell disease-related retinopathy.

Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register, compiled from electronic database searches and handsearching of journals and conference abstract books. Date of last search: 21 September 2015.We also searched the following resources (24 March 2015): Latin American and Carribean Health Science Literature Database (LILACS); WHO International Clinical Trials Registry Platforms (ICTRP); and ClinicalTrials.gov.

Selection criteria: Randomised controlled trials comparing laser photocoagulation to no treatment in children and adults.

Data collection and analysis: Two authors independently assessed trial eligibility, the risk of bias of the included trials and extracted and analysed data. We contacted the trial authors for additional information.

Main results: Two trials (341 eyes of 238 children and adults) were included comparing efficacy and safety of laser photocoagulation to no therapy in people with proliferative sickle retinopathy. There were 121 males and 117 females with an age range from 13 to 67 years. The laser photocoagulation technique used was different in the two trials; one single-centre trial employed sectoral scatter laser photocoagulation using an argon laser; and the second, two-centre trial, employed feeder vessel coagulation using argon laser in one centre and xenon arc in the second centre. The follow-up period ranged from a mean of 21 to 32 months in one trial and 42 to 47 months in the second. Both trials were at risk of selection bias (random sequence generation) because of the randomisation method employed for participants with bilateral disease. One study was considered to be at risk of reporting bias.Using sectoral scatter laser photocoagulation, one trial (174 eyes) reported that complete regression of proliferative sickle retinopathy was seen in 30.2% in the laser group and 22.4% in the control group (no difference between groups). The same trial reported the development of new proliferative sickle retinopathy in 34.3% of laser-treated eyes and in 41.3% of eyes given no treatment; again, there was no difference between treatment groups. The second trial, using feeder vessel coagulation, did not present full data for either treatment group for these outcomes.There was evidence from both trials (341 eyes) that laser photocoagulation using scatter laser or feeder vessel coagulation may prevent the loss of vision in eyes with proliferative sickle retinopathy (at median follow up of 21 to 47 months). Data from both trials indicated that laser treatment prevented the occurrence of vitreous haemorrhage with both argon and xenon laser; with the protective effect being greater with feeder vessel laser treatment compared to scatter photocoagulation.Regarding adverse effects, the incidence of retinal tear was minimal, with only one event reported. Combined data from both trials were available for 341 eyes; there was no difference between the laser and control arms for retinal detachment. In relation to choroidal neovascularization, treatment with xenon arc was found to be associated with a significantly higher risk, but visual loss related to this complication is uncommon with long-term follow up of three years or more.Data regarding quality of life and other adverse effects were not reported in the included trials.

Authors' conclusions: Our conclusions are based on the data from two trials conducted over 20 years ago. In the absence of further evidence, laser treatment for sickle cell disease-related retinopathy should be considered as a one of therapeutic options for preventing visual loss and vitreous haemorrhage. However, it does not appear to have a significant different effect on other clinical outcomes such as regression of proliferative sickle retinopathy and development of new ones. No evidence is available assessing efficacy in relation to patient-important outcomes (such as quality of life or the loss of a driving licence). There is limited evidence on safety, overall, scatter argon laser photocoagulation is superior in terms of adverse effects, although feeder vessel coagulation has a better effect in preventing vitreous haemorrhage. Further research is needed to examine the safety of laser treatment compared to other interventions such as intravitreal injection of anti-vascular endothelial growth factors. In addition, patient-important outcomes as well as cost-effectiveness should be addressed.

PubMed Disclaimer

Conflict of interest statement

All authors: none known.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included trial.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Farber 1991 {published data only}
    1. Farber MD, Jampol LM, Fox P, Moriarty BJ, Acheson RW, Rabb MF, et al. A randomized clinical trial of scatter photocoagulation of proliferative sickle cell retinopathy. Archives of Ophthalmology 1991;109(3):363‐7. [] - PubMed
    1. Fox PD, Minninger K, Forshaw ML, Vessey SJ, Morris JS, Serjeant GR. Laser photocoagulation for proliferative retinopathy in sickle haemoglobin C disease. Eye (London, England) 1993;7(Pt 5):703‐6. [] - PubMed
    1. Jampol LM, Farber M, Rabb MF, Serjeant G. An update on techniques of photocoagulation treatment of proliferative sickle cell retinopathy. Eye (London, England) 1991;5:260‐3. [] - PubMed
Jampol 1983 {published data only}
    1. Condon P, Jampol LM, Farber MD, Rabb M, Serjeant G. A randomized clinical trial of feeder vessel photocoagulation of proliferative sickle cell retinopathy. II. Update and analysis of risk factors. Ophthalmology 1984;91(12):1496‐8. [] - PubMed
    1. Jacobson MS, Gagliano DA, Cohen SB, Rabb MF, Jampol LM, Farber MD, et al. A randomized clinical trial of feeder vessel photocoagulation of sickle cell retinopathy. A long‐term follow‐up. Ophthalmology 1991;98(5):581‐5. [] - PubMed
    1. Jampol LM, Condon P, Farber M, Rabb M, Ford S, Serjeant G. A randomized clinical trial of feeder vessel photocoagulation of proliferative sickle cell retinopathy. I. Preliminary results. Ophthalmology 1983;90(5):540‐5. [] - PubMed
    1. Jampol LM, Farber M, Rabb MF, Serjeant G. An update on techniques of photocoagulation treatment of proliferative sickle cell retinopathy. Eye (London, England) 1991;5:260‐3. [] - PubMed

References to studies excluded from this review

Acheson 1991 {published data only}
    1. Acheson RW, Fox PD, Chuang EL, Serjeant GR. Treatment of iatrogenic choriovitreal neovascularisation in sickle cell disease. British Journal of Ophthalmology 1991;75(12):729‐30. [] - PMC - PubMed
Condon 1974 {published data only}
    1. Condon PI, Serjeant GR. Photocoagulation in sickle cell retinopathy [abstract]. Commonwealth Caribbean Medical Research Council, 19th Scientific Meeting; 1974 April 26‐29; Mona, Jamaica. 1974:1‐2. []
Lemaire 2013 {published data only}
    1. Lemaire C, Lamarre Y, Lemonne M, Waltz X, Chahed S, Cabot F, et al. Severe proliferative retinopathy is associated with blood hyperviscosity in sickle cellhemoglobin‐C disease but not in sicklecell anemia. Clinical Hemorheology and Microcirculation 2013;55:205‐11. [DOI: 10.3233/CH-2012-1622] - DOI - PMC - PubMed
Osuji 2003 {published data only}
    1. Osuji NC, Majone B, Lumley H, Day A, O'Sullivan E, Alwis D. Screening for sickle retinopathy: a new, rapid and effective approach using the panoramic 200 panretinal camera [abstract]. British Journal of Haematology 2003;121 Suppl 1:43‐4. []

References to studies awaiting assessment

Sayag 2008 {published data only}
    1. Sayag D, Binaghi M, Souied E, Pawlak D, Galacteros F, Coscas G, et al. Peripheral retinal scatter photocoagulation for the treatment of proliferative sickle retinopathy: a prospective clinical trial with new sea fan classification. European Journal of Ophthalmology 2008;18(2):248‐54. [CENTRAL: 638176;CRS:5500050000000040; PUBMED: 18320518] - PubMed
    1. Sayag D, Binaghi M, Souied E, Pawlak D, Galacteros F, Coscas G, et al. Peripheral retinal scatter photocoagulation for the treatment of proliferative sickle retinopathy: is it always indispensable?. IOVS 2004; Vol. 45:AVO E‐Abstract:5266. [CENTRAL: 598655;CRS: 5500050000000039]

Additional references

Abiose 1978
    1. Abiose A, Lesi FE. Ocular findings in children with homozygous sickle cell anaemia in Nigeria. Journal of Paediatric Ophthalmology and Strabismus 1978;15(2):92‐5. - PubMed
Ballas 2010
    1. Ballas SK, Leiff S, Benjamin LJ, Dampier CD, Heeney MM, Hoppe C, et al. Definitions of phenotypic manifestations of sickle cell disease. American Journal of Haematology 2010;85(1):6‐13. [DOI: 10.1002/ajh.21550] - DOI - PMC - PubMed
Ballas 2012
    1. Ballas SK, Kesen MR, Goldberg MF, Lutty GA, Dampier K, Osunkwo I, et al. Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. The Scientific World Journal http://www.hindawi.com/journals/tswj/2012/949535 (accessed 15 April 2013). [DOI: 10.1100/2012/949535] - DOI - PMC - PubMed
Castro 1999
    1. Castro O. Management of sickle cell disease: recent advances and controversies. British Journal of Haematology 1999;107(1):2‐11. - PubMed
Cohen 1986
    1. Cohen SB, Fletcher ME, Goldberg MF, Jednock NJ. Diagnosis and management of ocular complications of sickle haemoglobinopathies: part IV. Ophthalmic Surgery 1986;17(5):312‐5. - PubMed
Condon 1972
    1. Condon PI, Serjeant GR. Ocular findings in homozygous sickle cell anaemia in Jamaica. American Journal of Ophthalmology 1972;73(4):533‐4. - PubMed
Condon 1974a
    1. Condon PI, Gray R, Serjeant GR. Ocular findings in children with sickle cell haemoglobin C disease in Jamaica. British Journal of Ophthalmology 1974;58(7):644‐9. - PMC - PubMed
Condon 1974b
    1. Condon PI, Serjeant GR. Photocoagulation and diathermy in the treatment of proliferative sickle retinopathy. British Journal of Ophthalmology 1974;58(7):650‐62. - PMC - PubMed
Cruess 1983
    1. Cruess AF, Stephens RF, Magargal LE, Brown GC. Peripheral circumferential retinal scatter photocoagulation for treatment of proliferative sickle retinopathy. Ophthalmology 1983;90(3):272‐8. - PubMed
Deeks 2011
    1. Deeks J, Higgins JPT, Altman D (editors). Chapter 9: Analysing data and undertaking meta‐analysis. In: Higgins JPT, Green S (editors). In Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011].The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Downes 2005
    1. Downes SM, Hambleton IR, Chuang EL, Lois N, Serjeant GR, Bird AC. Incidence and natural history of proliferative sickle cell retinopathy: observation from a cohort study. Ophthalmology 2005;112(11):1869‐75. - PubMed
Elagouz 2010
    1. Elagouz M, Jyothi S, Gupta B, Sivaprasad S. Sickle cell disease and the eye: old and new concepts. Survey of Ophthalmology 2010;55(4):359‐77. - PubMed
Emerson 2005
    1. Emerson GG, Lutty GA. Effects of sickle cell disease on eye: clinical features and treatment. Hematology/Oncology Clinics of North America 2005;19(5):957‐73. - PubMed
Emerson 2006
    1. Emerson GE, Harlan JB, Fekrat S, Lutty GA, Goldberg MF. Hemoglobinopathies. In: Ryan SJ editor(s). Retina. 4th Edition. Vol. 2, Edinburgh: Elsevier, 2006:1429‐45.
Erachulu 2006
    1. Erachulu UV, Pam VA, Akuse RM. Ocular findings in children with severe clinical symptoms of homozygous sickle cell anaemia in Kaduna, Nigeria. West African Journal of Medicine 2006;25(2):88‐91. - PubMed
Evans 2014
    1. Evans JR, Michelessi M, Virgili G. Laser photocoagulation for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, Issue 11. [DOI: 10.1002/14651858.CD011234.pub2] - DOI - PMC - PubMed
Fox 1991
    1. Fox PD, Vessey SJR, Forshaw ML, Serjearnt GR. Influence of genotype on the natural history of untreated proliferative sickle retinopathy. British Journal of Ophthalmology 1991;75(4):229‐31. - PMC - PubMed
Fox 1993
    1. Fox PD, Minninger K, Forshaw ML, Vessey SJ, Morris JS, Serjeant GR. Laser photocoagulation for proliferative retinopathy in sickle haemoglobin C disease. Eye (London, England) 1993;7(Pt 5):703‐6. [] - PubMed
Goldbaum 1979
    1. Goldbaum MH, Fletcher RC, Jampol LM, Goldberg MF. Cryotherapy for proliferative sickle retinopathy,II: a triple freeze‐thaw cycle. British Journal of Ophthalmology 1979;63(2):97‐101. - PMC - PubMed
Goldberg 1971
    1. Goldberg MF. Natural history of untreated proliferative sickle retinopathy. Archives of Ophthalmology 1971;85(4):428‐37. - PubMed
Goldberg 1983
    1. Goldberg MF, Jampol LM. Treatment of neovascularization, vitreous haemorrhage and retinal detachment in sickle cell retinopathy. Transactions of the New Orleans Academy of Ophthalmology 1983;31:58‐81. - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins PT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. Available from www.cochrane‐handbook.org.
Hirst 2012
    1. Hirst C, Owusu‐Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD003427.pub2] - DOI - PubMed
Kimmel 1986
    1. Kimmel AS, Magagal LE, Stephens RS, Cruess AF. Peripheral circumferential retinal scatter photocoagulation for the treatment of proliferative sickle retinopathy. An update. Ophthalmology 1986;93(11):1429‐34. - PubMed
Lutty 1994
    1. Lutty GA, Goldberg MF. Ophthalmologic complications. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH editor(s). Sickle cell disease: Basic principle and clinical practice. New York: Raven Press, 1994:703‐24.
Marti‐Carvajal 2012
    1. Marti‐Carvajal AJ, Knight‐Madden JM, Martinez‐Zapata MJ. Interventions for treating leg ulcers in people with sickle cell disease. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD008394.pub2] - DOI - PubMed
Moriaty 1988
    1. Moriaty BJ, Acheson RW, Condon PI, Serjeant GR. Patterns of visual loss in untreated sickle cell retinopathy. Eye 1988;2(Pt 3):330‐5. - PubMed
Myint 2013
    1. Myint KT, Sahoo S, Moe S, Ni H. Laser therapy for retinopathy in sickle cell disease. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD010790] - DOI - PMC - PubMed
Penman 1994
    1. Penman AD, Talbot AF, Chuang EL, Thomas P, Serjeant GR, Bird AC. New classification of peripheral retinal vascular changes in sickle cell disease. Bnrtish Journal ofOphthalmology 1994;78:681‐9. - PMC - PubMed
Rednam 1982
    1. Rednam KRV, Jampol IM, Goldberg MF. Scatter retinal photocoagulation for proliferative sickle cell retinopathy. American Journal of Ophthalmology 1982;93(5):594‐9. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2014.
Roberts 2007
    1. Roberts I, Montalembert M. Sickle cell disease as a paradigm of immigration hematology: new challenges for haematologists in Europe. Haematologica 2007;92(07):865‐92. - PubMed
Seiberth 2001
    1. Seiberth V. Transscleral and transpupillary laser coagulation in proliferative sickle‐cell retinopathy. Ophthalmologe 2001;98(2):199‐202. - PubMed
Serjeant 2001
    1. Serjeant GR. The emerging understanding of sickle cell disease. British Journal of Haematology 2001;112(1):3‐18. - PubMed
Shaikh 2008
    1. Shaikh S. Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy. Indian Journal of Ophthalmology 2008;56(3):259. - PMC - PubMed
Siqueira 2006
    1. Siqueira RC, Costa RA, Scott IU, Cintra LP, Jorge R. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. Acta Ophthalmologica Scandinavica 2006;84:834‐5. [DOI: 10.1111/j.1600-0420.2006.00779.x] - DOI - PubMed
Virgili 2009
    1. Virgili G, Bini A. Laser photocoagulation for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD004763.pub2] - DOI - PubMed
Weatherall 2001
    1. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problems. Bulletin of the World Health Organization 2001;79(8):1‐15. - PMC - PubMed

Publication types